De-risk your drug development with HUB Organoids®
PDO Screen
The only organoid-based screening platform customizable to your drug development needs
PDO Screen is built upon the recent success of our organoid screening platform which led to the first oncology agent to be approved for clinical trials within 5 years of development.
Select from an extensive panel of well-characterized patient-derived organoids from multiple epithelial tissue types, disease indications, and mutational signatures to evaluate efficacy and prioritize your lead candidate with confidence.
